Clinical trial
A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery
NCT02610283 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery
- Lead sponsor
- Quark Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2015
- Completion date
- April 30, 2018
- Enrollment
- 341 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.